These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 15231250)
1. New drugs for treatment of multiple myeloma. Bruno B; Rotta M; Giaccone L; Massaia M; Bertola A; Palumbo A; Boccadoro M Lancet Oncol; 2004 Jul; 5(7):430-42. PubMed ID: 15231250 [TBL] [Abstract][Full Text] [Related]
3. The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma. Kalmadi SR; Hussein MA Acta Haematol; 2006; 116(1):1-7. PubMed ID: 16809883 [TBL] [Abstract][Full Text] [Related]
4. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Ocio EM; Mateos MV; Maiso P; Pandiella A; San-Miguel JF Lancet Oncol; 2008 Dec; 9(12):1157-65. PubMed ID: 19038762 [TBL] [Abstract][Full Text] [Related]
6. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Rajkumar SV; Witzig TE Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136 [TBL] [Abstract][Full Text] [Related]
9. Drug insight: thalidomide as a treatment for multiple myeloma. Kumar S; Anderson KC Nat Clin Pract Oncol; 2005 May; 2(5):262-70. PubMed ID: 16264962 [TBL] [Abstract][Full Text] [Related]
10. Targeting multiple myeloma cells and their bone marrow microenvironment. Pagnucco G; Cardinale G; Gervasi F Ann N Y Acad Sci; 2004 Dec; 1028():390-9. PubMed ID: 15650264 [TBL] [Abstract][Full Text] [Related]
11. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Anderson KC Exp Hematol; 2007 Apr; 35(4 Suppl 1):155-62. PubMed ID: 17379101 [TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor and its receptors in multiple myeloma. Ria R; Roccaro AM; Merchionne F; Vacca A; Dammacco F; Ribatti D Leukemia; 2003 Oct; 17(10):1961-6. PubMed ID: 14513045 [TBL] [Abstract][Full Text] [Related]
14. [Bone marrow angiogenesis in multiple myeloma: new insights into the pathogenesis, and development of a new therapeutic approach]. Hattori Y; Kakimoto T Rinsho Ketsueki; 2000 May; 41(5):426-9. PubMed ID: 10879105 [No Abstract] [Full Text] [Related]
15. Antiangiogenesis in myelodysplastic syndrome. Aguayo A; Armillas-Canseco FM; Martínez-Baños D Curr Cancer Drug Targets; 2011 Nov; 11(9):1044-52. PubMed ID: 21999628 [TBL] [Abstract][Full Text] [Related]
16. Thalidomide: present and future in multiple myeloma. Hussein MA Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435 [TBL] [Abstract][Full Text] [Related]
17. Overview of drug therapy for multiple myeloma. Saunders G J Oncol Pharm Pract; 2005 Sep; 11(3):83-100. PubMed ID: 16390597 [TBL] [Abstract][Full Text] [Related]